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Lithium enhances cortical mRNA expression in ovariectomized
C57BL/6J mice
James J. Valdés, Franchesca M. Ramirez, Barbara Juarez and Ophelia I. Weeks*
Department of Biological Sciences, Florida International University, Florida, USA; *Email: weekso@fiu.edu
The hippocampus and cortex of the mammalian brain are regions involved in learning and long-term memory. Estrogen and
lithium affect similar learning and memory molecular processes. We hypothesized that in ovariectomized mice lithium
treatment will enhance genetic factors in the brain that are involved in neuroprotection, learning and memory. Our study used
bilaterally ovariectomized (bOVX) C57BL/6J mice treated for one month with 14.2 mM LiCl in their drinking water. Results
indicate that LiCl-treated bOVX mice show enhanced cortical increases in mRNA expression of ER-α, NR1, Bcl-2, BDNF,
and CaMkII-α; hippocampal mRNA showed no changes. Our results indicate that in bOVX C57BL/6J mice, lithium
enhances the expression of specific cortical genes coded for proteins involved in learning, memory and neuroprotection.
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INTRODUCTION
The literature indicates that estrogen-mediated
neuromechanisms enhance synaptic plasticity (Leranth
et al. 2002), reduce apoptotic activity in cortical neurons (Honda et al. 2001), and facilitate activation of
transcription factor, cyclic adenosine monophosphate
(cAMP) responsive element binding protein (CREB)
(McEwen 2001). Women typically reach menopause by
their late 40s to mid-50s and estrogen replacement
therapy (ERT) is commonly prescribed during peri- and
post-menopause. Also, pre-menopausal ovariectomized
(OVX) women suffering from benign diseases are usually prescribed ERT. Women prescribed ERT are potentially at risk, since there is an increased incidence of
lobular carcinoma associated with ERT (Newcomer et
al. 2003). Other studies indicate that ERT does not
improve cognition during menopause, specifically episodic memory (Henderson 2009). Therefore, an alternative therapy, especially one that provides assistance
with estrogen–mediated protein-signaling pathways
and positively affects cognition offers far-reaching benefits.
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Estrogen influences several neuroanatomically-specific behavioral tasks (Simpkins et al. 1997). Estrogen
receptor-α (ER-α) knockout mice and OVX mice perform poorly on hippocampal-dependent behavioral
tasks, suggesting that estrogen and ER-α expression
influence cognitive-behavioral performance levels
(Fugger et al. 2000). Although ER-β is also known to
influence behavior, ER-β signaling pathways are more
specific to visuospatial performance (e.g., Morris
water maze) and anxiety (Bodo and Rissman 2006).
Co-localization of ER-α and brain derived neurotrophic
factor (BDNF) are observed in pyramidal cells of the
hippocampus, and estrogen influences BDNF expression (Solum and Handa 2002). Ligand binding of
BDNF to tyrosine receptors initiates a signaling cascade that results in activating CREB (Blanquet et al.
2003), and facilitating CREB-mediated gene expression via N-methyl-D-aspartate receptor (NMDAR)
signaling pathways (Wheeler and Cooper 2004). Rats
with ovarian steroid deprivation (via simulating postpartum depression) show ephemeral gene expression
of calcium/calmodulin-dependent protein kinase II
(CaMkII), a kinase associated with increasing synaptic
plasticity and cognition (Suda et al. 2008).
Lithium, traditionally used to treat bipolar disorder, affects several molecular pathways via glycogen
synthase kinase-3beta (GSK-3β) inhibition (Jope
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2003) and by inositol monophosphatase inhibition
resulting in depleting amounts of free inositol
(Harwood 2004). Inhibition of GSK-3β is correlated
with reduced apoptotic activity (Hongisto et al.
2003), increased neurotrophic factor expression
(Angelucci et al. 2003), and facilitated CREB response
element binding (Ozaki and Chuang 1997, Grimes
and Jope 2001). Lithium’s neuroprotective properties
are also ascribed to increased levels of the anti-apoptotic agent B-cell lymphoma/leukemia-2 (Bcl-2) and
BDNF – this increase being associated with inhibition of GSK-3β and NMDAR tyrosine phosphorylation in primary rat cultures of cortical cells (Chuang
2005). Studies also show that lithium augments
expression of a specific CaMk isoform in rat brain
(Rushlow et al. 2009), and that low activity of
CaMkII is observed in the cortex of lithium-treated
rats (Celano et al. 2003).
Both estrogen and lithium facilitate transcriptional
properties of CREB by activating promoting factors of
CREB and/or inhibiting negative regulators of CREB
(Grimes and Jope 2001, McEwen 2001). We hypothesize that LiCl-treated OVX mice will enhance mRNA
expression of factors important in learning, memory
and neuroprotection in the brain (namely, ER-α,
NMDAR critical subunit NR1, Bcl-2, BDNF and
CaMkII-α). To test our hypothesis we treated bilaterally OVX (bOVX LiCl) C57BL/6J mice with 14.2 mM
LiCl for 1 month beginning two weeks post-bOVX
surgery. Our results show that LiCl treatment enhances
genetic factors involved in learning, memory and neuroprotection.
METHODS
Subjects, surgery and treatment
All experiments described in this study were
approved by the Florida International University
Institutional Animal Care and Use Committee (IACUC
protocol #: 08-017). C57BL/6J female mice (n=20)
were purchased from Jackson Laboratories. Animals
were housed within a facility maintained at 20-22°C,
60% humidity, within polycarbonate transparent cages
(26.7×20.6×14 cm) on a 12-hour day-night cycle with
free access to water and food.
At 4.5 months of age, mice weighing 21.5 g – 22.5 g
were anesthetized with ether and, aseptically, their
ovaries were removed bilaterally (e.g. bOVX). Mice

were positioned dorsal side up and for each surgical
procedure, parallel to the long axis of the animal’s
body, an incision ¾ cm in length was made ½ cm from
the rostral edge of the bony hip. Each fallopian tube
was located bilaterally and both ovaries were removed
and the transection site cauterized. Treatment with
14.2 mM LiCl in their drinking water that contained
0.9% saline began at 5 months of age for 1 month; LiCl
at 14.2 mM maintains lithium blood content at a subtherapeutic range (0.1–0.5 mM) (Sadeghipour-Roudsari
et al. 1998). The control group (Sham) received drinking water with 0.9% saline. All animals were divided
into four groups (LiCl-treated bOVX and Sham;
saline-treated bOVX and Sham). Sham animals
received the incision, the fallopian tube located and
ovaries identified, but not removed, and the incision
site was sutured.
Uterine and bone weight
All mice (n=20) were anesthetized with ether and
then euthanized via cervical dislocation. Brain, uteri,
femora and humeri were removed from each experimental mouse. Each uterus was weighed and inspected
to assure complete removal of ovaries during bOVX
surgery. Bones were cleaned of soft tissue and dried at
70°C for 24 h, then weighed.
Enzyme linked immunosorbent assay (ELISA)
Prior to cervical dislocation, 500-750 μl of blood
was drawn from the tail of each subject (n=20) to measure 17β-Estradiol (E2) level. Murine plasma was
isolated via centrifugation at 600×g for 15 min after a
4°C overnight storage with 6% EDTA. We performed
the ELISA using an Estradiol EIA kit (96 well kit;
Cayman Chemical Company, Ann Arbor, MI) according to the manufacturer’s protocol. Briefly, murine
plasma (100–300 µL) was purified using ethyl ether,
organic phase was isolated and the remaining ether
was evaporated with a gentle stream of N2 gas at room
temperature. Purified residue was then diluted with
EIA buffer (100–300 µL) and assayed in duplicates.
After 1 hour incubation with estradiol EIA antiserum
and estradiol-acetylcholinesterase tracer, the
microplate was developed for 45 min using Ellman’s
reagent and absorbance units measured using an ELX
Ultra Microplate Reader (Bio-Tek Instruments Inc.,
Winooski, VT).
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Total RNA isolation and reverse transcription
(RT)
Total RNA was isolated from brain tissue (n=12)
using TRIzol reagent (GIBCO, Carlsbad, CA), according to the manufacturer’s protocol. Briefly, the brain
was removed from each subject; the cortex and hippocampus from each hemisphere were isolated under a
Leica ZOOM 200 dissecting microscope, weighed,
and rinsed with Dulbecco’s Phosphate Buffer Saline
(DPBS). A 1:10 mass: TRIzol reagent was added then
homogenized with an IKA homogenizer (at speed 5 for
10 s). Chloroform was added and centrifuged at 12
000×g for 15 min at 4°C. After phase separation, total
RNA (aqueous phase) was then precipitated with isopropanol and RNA was pelleted via centrifugation.
Total RNA pellet was washed with 75% ethanol and
then resuspended in DEPC-treated water. To remove
any DNA containments we used RQ1 DNase kit
(Promega, Madison, WI). An aliquot of samples was
used for concentrations and purity quantification using
absorptions at 260 nm and 280 nm.
First strand cDNA synthesis was performed using
SUPERSCRIPTTM III RNase H-free reverse transcriptase (Invitrogen, Carlsbad, CA), according to the
manufacturer’s protocol. Briefly, 3 µg of total RNA
was reverse transcribed with 0.05 µg/µl of Oligo (dT)20
at 65°C for 5 min. First strand cDNA was synthesized
with Superscript III/RNase OUT Enzyme mix and
incubated at 50°C for 50 min; reaction was terminated
at 85°C for 5 min. RNase H (Invitrogen, Carlsbad, CA)
was added once first strand was synthesized to remove
any remaining RNA. RNase H was incubated at 37°C
for 20 min. Samples were stored at -20°C until further
processing.
Quantitative real-time polymerase chain
reaction (PCR)
First strand cDNA was amplified via real time PCR
using SYBR Green PCR master mix (ThermoScientific,
Rockford, IL), 200-300 nM of forward and reverse
primers using AB 7300 Real Time PCR system.
Cycling parameters were set at: 95°C 30 s, 57–63°C 30
s, and extension at 72°C for 30 s, for a total of 40
cycles, followed by a final extension at 72°C for 10
min. The specific primer pairs were: ER-α: forward
primer, 5’-AAGGGCAGTCACAATGAACC-3; reverse
primer, 5’-GCCAGGTCATTCTCCACATT-3’ (PCR

efficiency = 94%); NMDAR subunit NR1: forward
primer, 5’-ACTCCCAACGACCACTTCAC-3; reverse
primer, 5’-GTAGACGCGCATCATCTCAA-3’ (PCR
efficiency = 90%); Bcl-2: forward primer, 5’-AGGAGCAGGTGCCTACAAGA-3;
reverse
primer,
5’-GCATTTTCCCACCACTGTCT-3’ (PCR efficiency
= 101%); BDNF: forward primer, 5’-ATCCAAATATGGCACAGCAA-3; reverse primer, 5’-TTCTGCCTGAGTTTTGATGC-3’ (PCR efficiency = 100%);
CaMkII-α forward 5’-GGGTTTGGCTCTTGTATGGA-3’, reverse 5’-CTCTCCGTGCTTTTGGTCTC-3’
(PCR efficiency = 99%). The endogenous control was
HPRT: forward primer, 5’-GGAGCGGTAGCACCTCCT-3’; reverse primer, 5’-AATCCAGCAGGTCAGCAAAG-3’ (PCR efficiency = 86%). All samples were
compared with a standard curve comprised of pDNA
generated using TOPO TA Cloning® Kit (Invitrogen,
Carlsbad, CA). Readings were normalized by dividing
interest gene number of mRNA copies by the housekeeping gene (HPRT) number of copies; the output is
this ratio.
Statistical analysis
Data are presented as the mean ± S.E.M and statistical significance was determined by an analysis of variance (ANOVA) or a multiple analysis of variance
(MANOVA) followed by a Fisher’s least significant
difference (LSD) post-hoc procedure. Significant differences were those having a P-value<0.05.
RESULTS
E2 plasma levels
There is an obvious trend in Fig. 1, suggesting a
rescue in lithium-treated bOVX mice E2 plasma level.
No significant differences, however, were detected in
plasma E2 content across treatment groups (Fig. 1;
F3,15=0.7, P>0.5).
Uterine and bone weight
Statistical analysis using ANOVA indicated that
uterine weight was significantly less (F3,16=45.1,
P<0.001) in bOVX mice (non-treated and treated)
compared with Sham mice (non-treated and treated),
but post-hoc testing detected no significant differences
(P>0.8) between LiCl-treated and non-treated groups
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(Fig. 2A). Using MANOVA, we analyzed dry bone
weight from experimental mice and noted no significant differences in both humeri (Fig. 2B; F3,28=2.1,
P>0.1) or femora (Fig. 2C; F3,28=2.6 P>0.07) across
treatment groups; however, Fisher’s LSD post-hoc testing indicated significant decreases in humeri weight
(P<0.02) for LiCl-treated bOVX mice compared with
LiCl-treated Sham and in femora weight (P<0.02)
when LiCl-treated bOVX mice are compared with the
other treatment groups (Fig. 2B).
Gene expression is enhanced by LiCl in the
cortex of bOVX mice

Murine Plasma E2 level (pg/mL)

Statistical analysis using MANOVA indicated significant differences between cortical and hippocampal
gene expression: ER-α (Fig. 3A; F1,14=6.1, P<0.03),
NR1 (Fig. 3B; F1,14=13.2, P<0.003), Bcl-2 (Fig. 3C;
F1,14=36.1, P<0.001), BDNF (Fig. 3D; F1,14=20.8,
P<0.001), and CaMkII-α (Fig. 3E; F1,14=19.2, P<0.001)
– ER-α (Fig. 3A), NR1 (Fig. 3B), and CaMkII-α (Fig.
3E) mRNA were expressed higher in the cortex, while
Bcl-2 (Fig. 3C) and BDNF (Fig. 3D) showed higher
mRNA expression in the hippocampus. Statistical
analysis using MANOVA also detected significant differences for ER-α (Fig. 3A; F3,14=3.5, P<0.05) and NR1
mRNA (Fig. 3B; F3,14=3.6, P<0.05) across treatment
groups. Statistical analysis, however, noted no significant differences in mRNA expression across treatment
groups for Bcl-2 (Fig. 3C; F3,14=1.1, P>0.3), BDNF (Fig.
3D; F3,14=1.6, P>0.2), or CaMkII-α (Fig. 3E; F3,14=3.3,
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Fig. 1
17β-Estradiol (E2) content in murine plasma as measured
via enzyme-linked immunosorbent assay (ELISA). Units for
E2 content are in pg/mL (y-axis). Data are presented as the
mean ± S.E.M

P>0.05). No significant differences were noted for the
interaction between brain region and treatment group
for ER-α (F3,14=0.2, P>0.9), NR1 (F3,14=2.9, P>0.07),
Bcl-2 (F3,14=1.0, P>0.4), and BDNF (F3,14=0.04, P>0.9),
except for CaMkII-α (F3,14=3.7, P<0.05).
Since a significant difference was noted for brain
region we performed a MANOVA for the hippocampus and cortex, separately. No significant differences
in the hippocampus were noted for each gene: ER-α
(Fig. 3A; F3,7=0.9, P>0.4), NR1 (Fig. 3B; F3,7=1.5,
P>0.4), Bcl-2 (Fig. 3C; F3,7=1.0, P>0.4), BDNF (Fig.
3D; F3,7=0.0, P>0.7), and CaMkII-α (Fig. 3E; F3,7=0.7,
P>0.5). Cortical mRNA, however, showed significant
values for all genes except for NR1 (Fig. 3B; F3,7=3.8,
P>0. 1), ER-α (Fig. 3A; F3,7=4.9, P<0.05), Bcl-2 (Fig.
3C; F3,7=13.2, P<0.003), BDNF (Fig. 3D; F3,7=6.1,
P<0.025), and CaMkII-α (Fig. 3E; F3,7=4.9, P<0.05).
Fisher’s LSD post-hoc testing on cortical mRNA indicated that all genes showed significant increases in
expression (P<0.05) for LiCl-treated bOVX when
compared with all other treatment groups (Fig.
3A-3E).
DISCUSSION
We noted no differences in E2 plasma levels across
treatment groups (Fig. 1; experimental mice showed
35–40 pg/ml E2 plasma level – indicative of E2 levels
during the proestrous cycle); however, removal of the
ovaries resulted in uterine atrophy since we clearly
show that uterine weight of bOVX mice was significantly lower compared with Sham mice (Fig. 2A). The
non-significant output of E2 plasma levels (Fig. 1) may
be due to treatment duration and biological differences
between our replicates. Investigations have noted that
there is an individual-dependent variation with mood
stabilizing drugs (Lerer and Macciardi 2002); however, extending lithium treatment for bOVX mice may
cause a significant increase in E2 plasma levels since
there is a noticeable trend in our current study (Fig. 1).
Lithium is reported to increase cell proliferation and
hyperplasia in murine uteri (Gunin et al. 2004), and
lithium treatment increases human (Zamani et al.
2009) and murine bone mass (Clement-Lacroix et al.
2005). In our study, we found no alterations in E2
plasma levels across treatment groups (Fig. 1), but
reduced uterine weight suggested successful removal
of ovaries (LiCl treatment caused no alterations in
uterine weight – see Fig. 2A). We also noted that bone
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density actually decreased in LiCl-treated bOVX mice
(Fig. 2B and 2C). An explanation eludes us regarding
decreased bone mass in LiCl-treated bOVX mice and
not non-treated bOVX, since the literature reports that
after 3.5 months post-bOVX surgery, murine bone
mass decreases (Masuda et al. 1997). Progesterone
also diminishes following bOVX surgery (Galeeva and
Tuohimaa 2001). Progesterone also affects uterine
(Murray and Stone 1989) and bone tissue (Horner
2009). Measuring progesterone plasma levels may provide further insight, and histology on bone and uteri
would provide a more detailed analysis on how our
treatment parameters affect the architecture of these
tissue types.
Previous research from our laboratory showed
that male C57BL/6J mice treated with 14.2 mM LiCl
display enhanced performance in a Morris Water
Maze and an object recognition task over a 5 month
treatment period (C-H Volmar, personal communication). Atomic absorption spectroscopy analyses of
these male mice showed that treatment with 14.2 mM
LiCl in their drinking water maintained a sub-therapeutic level of about 0.2 mM lithium in blood samples (CH Volmar, personal communication) – we
found higher dosages lethal to bOVX mice. Blood
samples at therapeutic levels range between 0.6-1.5
mM (Sadeghipour-Roudsari et al. 1998). Our present
findings indicate that LiCl-treated bOVX mice
showed enhanced cortical mRNA expression for
ER-α (Fig. 3A), NR1 (Fig. 3B), Bcl-2 (Fig. 3C),
BDNF (Fig. 3D) and CaMkII-α (Fig. 3E) compared
with all other treatment groups.
Our results show increased mRNA expression is
brain region-specific (Fig. 3A–3E; occurring in the
cortex but not the hippocampus). These findings are
consistent with the literature that lithium modulates
several genes (Manji et al. 2001) and that this modulation is brain-region specific (Jakobsen and Wiborg
1998). Increased gene expression only occurring in
LiCl-treated bOVX mice may be due to the bimodal
action of lithium. Although we noted no differences
in plasma levels of E2 (Fig. 1), removal of ovaries
does cause a withdrawal of circulating hormones,
but small amounts of hormones known as neurosteroids are still produced in the brain (Sierra 2004).
The bimodal action of lithium may be a plausible
explanation of our results. Jope (1999) proposes a
bimodal model for lithium, such that lithium regulates positive and negative cell signaling mecha-
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Fig. 2A-2C
Uterine (A) and bone weight (B & C) presented in mg
(y-axis). The humeri (B; right = grey bars; left = black bars)
and femora (C; right = grey bars; left = black bars) were
used for dry bone weight. *, represents significant increase
compared to bOVX; #, represents significant increase compared to Sham; †, represents significant increase compared
to Sham+LiCl. Data are presented as the mean ± S.E.M Data
are presented as the mean ± S.E.M
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Fig. 3A-3E
Hippocampal (grey bars) and cortical (black bars) mRNA expression for ER-α (A), NR1 (B), Bcl-2 (C), BDNF (D), and
CaMkII-α (E) using quantitative real time PCR. Units are represented as the number of mRNA copies (y-axis) for each respective gene (ratio of gene/HPRT). *, represents significant increase compared to bOVX; #, represents significant increase compared to Sham; †, represents significant increase compared to Sham+LiCl. Data are presented as the mean ± S.E.M
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nisms by stabilizing extreme and/or minimized
levels of integral factors involved in these cell signaling mechanisms. Lithium’s bimodal mechanism
may facilitate neurosteroidal-mediated brain cell
signaling in a hormone-deprived system (e.g.,
bOVX). Studies do indicate that the molecular
effects of lithium vary from acute to chronic treatment (Lenox and Watson 1994).
Although no significant differences were noted,
genetic expression did decrease for non-treated
bOVX mice in the hippocampus compared with
Sham mice; and there is, at least graphically, a notable rescue for hippocampal genes NR1 (Fig. 3B),
Bcl-2 (Fig. 3C) and CaMkII-α (Fig. 3E) in LiCltreated bOVX mice. We currently have preliminary
data indicating that protein levels are augmented in
the hippocampus of LiCl-treated bOVX mice (data
not shown). We do, however, need additional studies
using bOVX mice with chronic versus acute lithium
treatment and further investigations on how our
treatment parameters affect protein levels of ER-α,
NR1, Bcl-2, BDNF and CaMkII-α, are necessary to
explain the neuroanatomical discrepancies noted in
the current study.
CONCLUSION
Studies have shown that ERT reduces the development of neurodegenerative diseases and improves
cognition (Garcia-Segura et al. 2001, Wise 2002),
however, the latter has been recently challenged
(Henderson 2009). It seems that risks associated with
ERT outweigh its benefits, since ERT also increases
incidences of breast cancer (Newcomer et al. 2003).
Selective estrogen receptor modulators (SERMs) provide an alternative to ERT but studies show that
SERMs do not improve cognitive functioning (Natale
et al. 2004, Palmer et al. 2008). Post-menopausal and
OVX pre-menopausal women may also suffer from
cognitive decline if estrogen withdrawal is not immediately remedied (Sherwin 2005). Estrogen is essential
for normal brain function by facilitating factors
involved in learning, memory and neuroprotection.
An alternative therapy that mimics the beneficial
aspects of estrogen, without the harmful effects will
serve as a better treatment for women with depleted
ovarian steroids. The current study indicates that in
bOVX mice, lithium enhances brain region-specific
genetic factors that are involved in learning and mem-

ory (Fig. 3A–3E). Our data provides insight into
potential positive clinical implications for lithium and
how it may have beneficial promise for post-menopausal women or pre-menopausal OVX women. We
believe that this study should serve to drive further
investigations into lithium’s potential benefits as an
estrogen-mediated signaling modulator in an ovarian
steroidal-deprived system.
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